首页> 外文期刊>Haematologica >Analysis of human reticulocyte genes reveals altered erythropoiesis: potential use to detect recombinant human erythropoietin doping | Haematologica
【24h】

Analysis of human reticulocyte genes reveals altered erythropoiesis: potential use to detect recombinant human erythropoietin doping | Haematologica

机译:对人类网织红细胞基因的分析揭示了促红细胞生成改变:检测重组人促红细胞生成素的潜在用途血液学

获取原文
       

摘要

BACKGROUND AND OBJECTIVES: Enhancement of oxygen delivery to tissues is associated with improved sporting performance. One way of enhancing oxygen delivery is to take recombinant human erythropoietin (rHuEpo), which is an unethical and potentially dangerous practice. However, detection of the use of rHuEpo remains difficult in situations such as: i) several days after the end of treatment ii) when a treatment with low doses is conducted iii) if the rHuEpo effect is increased by other substances. In an attempt to detect rHuEpo abuse, we selected erythroid gene markers from a SAGE library and analyzed the effects of rHuEpo administration on expression of the HBB, FTL and OAZ genes. DESIGN AND METHODS: Ten athletes were assigned to the rHuEpo or placebo group. The rHuEpo group received subcutaneous injections of rHuEpo (50 UI/kg three times a week, 4 weeks; 20 UI/kg three times a week, 2 weeks). HBB, FTL and OAZ gene profiles were monitored by real time-polymerase chain reaction (PCR) quantification during and for 3 weeks after drug administration. RESULTS: The global analysis of these targeted genes detected in whole blood samples showed a characteristic profile of subjects misusing rHuEpo with a increase above the threshold levels. The individual analysis of OAZ mRNA seemed indicative of rHuEpo treatment. INTERPRETATION AND CONCLUSIONS: The performance-enhancing effect of rHuEpo treatment is greater than the duration of hematologic changes associated with rHuEpo misuse. Although direct electrophoretic methods to detect rHuEpo have been developed, recombinant isoforms of rHuEpo are not detectable some days after the last subcutaneous injection. To overcome these limitations indirect OFF models have been developed. Our data suggest that, in the near future, it will be possible to consolidate results achievable with the OFF models by analyzing selected erythroid gene markers as a supplement to indirect methods.
机译:背景和目的:增强向组织的氧气输送与改善运动表现有关。增强氧气输送的一种方法是服用重组人促红细胞生成素(rHuEpo),这是一种不道德且具有潜在危险的做法。但是,在以下情况下,检测rHuEpo的使用仍然很困难:i)治疗结束后的几天ii)进行低剂量治疗时iii)如果其他物质增加了rHuEpo的作用。为了检测rHuEpo的滥用,我们从SAGE文库中选择了类红细胞基因标记,并分析了rHuEpo给药对HBB,FTL和OAZ基因表达的影响。设计与方法:将10名运动员分配到rHuEpo或安慰剂组。 rHuEpo组接受皮下注射rHuEpo(每周4次,每周3次,每次50 UI / kg;每周2次,每周3次,每次20 UI / kg)。在给药期间和给药后3周,通过实时聚合酶链反应(PCR)定量监测HBB,FTL和OAZ基因概况。结果:对在全血样本中检测到的这些靶向基因的整体分析表明,滥用rHuEpo的受试者的特征性分布超过阈值水平。 OAZ mRNA的单独分析似乎表明了rHuEpo治疗。解释和结论:rHuEpo治疗的性能增强作用大于与rHuEpo滥用相关的血液学改变的持续时间。尽管已经开发出了直接电泳方法来检测rHuEpo,但在最后一次皮下注射后几天仍无法检测到rHuEpo的重组同工型。为了克服这些限制,已经开发了间接OFF模型。我们的数据表明,在不久的将来,通过分析选定的类红细胞基因标记作为间接方法的补充,可以巩固使用OFF模型可获得的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号